The fuzzy math of solid tumor stem cells: A perspective
The fuzzy math of solid tumor stem cells: A perspective
复制标题
DOI：
10.1158/0008-5472.can-07-1971
复制
发表时间：
2007-10-01
期刊：
影响因子：
11.2
通讯作者：
Shibata, Darryl
中科院分区：
文献类型：
--
作者：
Kern, Scott E.;Shibata, Darryl
表面上有效的治疗药物往往不能治愈癌症患者。因此，想知道是否应该识别并单独靶向特定的耐药细胞亚群是很有吸引力的。在实体肿瘤中，如癌症，已经提出并在人类肿瘤和分离的细胞群体中实验寻找一小部分“癌症干细胞”。人们经常忽视的是，理论基础和支持性数据本质上是数字的，可以这样评估。对已发表的研究和授予的美国专利中的相关权利要求进行重新评估表明，对治疗有用的干细胞概念的数学支持很弱，甚至可能使这些出版物和专利要求的基础无效。应该更一致地使用数学论证，因为它们可以作为解释实体肿瘤癌症干细胞研究的指南。
Apparently effective therapeutic agents very often fail to cure cancer patients. It is therefore attractive to wonder whether a specific resistant cell subset should be recognized and separately targeted. In solid tumors, such as carcinomas, a minor population of "cancer stem cells" has been proposed and sought experimentally in human tumors and isolated cell populations. It is often overlooked that the rationale and supportive data are essentially numerical and can be evaluated as such. A reevaluation of the published studies and related claims within awarded U.S. patents suggests that the mathematical support for the concept of therapeutically useful stem cells is weak and may even invalidate the foundations of these publications and patent claims. Mathematical arguments should be used more consistently, because they can serve as a guide for interpreting studies into cancer stem cells of solid tumors.